Freedom Fertility Pharmacy

freedomfertility.com

Freedom Fertility Pharmacy was founded in 1973 as Freedom Drug, a New Hampshire-based community retail pharmacy. With an emphasis on individualized patient care and superior customer service, Freedom prospered and expanded, opening locations throughout New England in the 70s and 80s. In the 1990s, Freedom focused its personalized approach on a growing segment of its business, women's health and infertility. In 1994, the company relocated to Lynnfield, MA, focusing its operations exclusively on infertility and speciality pharmacy services.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

HUATENG PHARMA DEVELOPS SPRAY AGAINST NEW CORONAVIRUS INFECTION

Huateng Pharma | February 11, 2020

news image

This year is an unusual year due to the infection of the Novel Coronavirus Pneumonia (NCP) epidemic. Hunan Huateng Pharmaceutical Co., Ltd. (hereinafter referred to as Huateng), as a drug research and development company with rich experience in developing antiviral drugs, has attached close attention to this matter. Considering that there is no targeted medicine for novel coronavirus pneumonia (NCP) infection and that NCP virus is highly similar to SARS / Middle East Respiratory Syndrome (MERS) ...

Read More

US CLINICAL TRIALS OF HYDROXYCHLOROQUINE HIT WARP SPEED COULD SHOW IN WEEKS

CNBC | April 15, 2020

news image

Researchers are working as quickly as science will allow to determine whether hydroxychloroquine, a decades-old malaria drug touted by President Donald Trump as a potential “game changer” in curtailing the Covid-19 pandemic, is effective in fighting the coronavirus. Federal health regulators have fast-tracked approvals for coronavirus research, allowing scientists across the nation to skip through months of red tape on potential treatments and vaccines for the deadly virus. On March ...

Read More

CHALLENGES FOR TRANSLATING PHARMACOMICROBIOMICS TO PERSONALIZED MEDICINE

News-Medical.Net | March 02, 2020

news image

A new Commentary identifies three actionable challenges for translating pharmacomicrobiomics to personalized medicine in 2020.Pharmacomicrobiomics is the study of how microbiome variations within and between individuals affect drug action, efficacy, and toxicity. This personalized medicine horizon scanning is featured in OMICS: A Journal of Integrative Biology, the peer-reviewed interdisciplinary journal published by Mary Ann Liebert, Inc., publishers. Ramy Aziz and Marwa ElRakaiby, Cairo Univer...

Read More

GILEAD, WORKING ON ITS OWN REMDESIVIR RAMP-UP, SCOUTS LICENSING PARTNERS FOR GLOBAL PRODUCTION

Fiercepharma | May 06, 2020

news image

Gilead Sciences can only produce so much of its newly authorized COVID-19 drug remdesivir, so it’s scouting other companies to bolster global supply. Even as it presses ahead with its own remdesivir ramp-up, Gilead says it’s in licensing talks with the “world’s leading chemical and pharmaceutical manufacturing companies” about their ability to produce remdesivir for countries in Europe, Asia and beyond until at least 2022. Remdesivir manufacturing relies on “s...

Read More
news image

HUATENG PHARMA DEVELOPS SPRAY AGAINST NEW CORONAVIRUS INFECTION

Huateng Pharma | February 11, 2020

This year is an unusual year due to the infection of the Novel Coronavirus Pneumonia (NCP) epidemic. Hunan Huateng Pharmaceutical Co., Ltd. (hereinafter referred to as Huateng), as a drug research and development company with rich experience in developing antiviral drugs, has attached close attention to this matter. Considering that there is no targeted medicine for novel coronavirus pneumonia (NCP) infection and that NCP virus is highly similar to SARS / Middle East Respiratory Syndrome (MERS) ...

Read More
news image

US CLINICAL TRIALS OF HYDROXYCHLOROQUINE HIT WARP SPEED COULD SHOW IN WEEKS

CNBC | April 15, 2020

Researchers are working as quickly as science will allow to determine whether hydroxychloroquine, a decades-old malaria drug touted by President Donald Trump as a potential “game changer” in curtailing the Covid-19 pandemic, is effective in fighting the coronavirus. Federal health regulators have fast-tracked approvals for coronavirus research, allowing scientists across the nation to skip through months of red tape on potential treatments and vaccines for the deadly virus. On March ...

Read More
news image

CHALLENGES FOR TRANSLATING PHARMACOMICROBIOMICS TO PERSONALIZED MEDICINE

News-Medical.Net | March 02, 2020

A new Commentary identifies three actionable challenges for translating pharmacomicrobiomics to personalized medicine in 2020.Pharmacomicrobiomics is the study of how microbiome variations within and between individuals affect drug action, efficacy, and toxicity. This personalized medicine horizon scanning is featured in OMICS: A Journal of Integrative Biology, the peer-reviewed interdisciplinary journal published by Mary Ann Liebert, Inc., publishers. Ramy Aziz and Marwa ElRakaiby, Cairo Univer...

Read More
news image

GILEAD, WORKING ON ITS OWN REMDESIVIR RAMP-UP, SCOUTS LICENSING PARTNERS FOR GLOBAL PRODUCTION

Fiercepharma | May 06, 2020

Gilead Sciences can only produce so much of its newly authorized COVID-19 drug remdesivir, so it’s scouting other companies to bolster global supply. Even as it presses ahead with its own remdesivir ramp-up, Gilead says it’s in licensing talks with the “world’s leading chemical and pharmaceutical manufacturing companies” about their ability to produce remdesivir for countries in Europe, Asia and beyond until at least 2022. Remdesivir manufacturing relies on “s...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us